This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the sinuses and nasal passages.1 Symptoms of CRSwNP include:2,3
Risks factors for developing CRSwNP include asthma and older age.5 Nearly two-thirds of patients with CRSwNP also have asthma, and patients with CRSwNP tend to get diagnosed in their 40s and 50s.4.6 In general, the condition affects more men than women.4
Chronic rhinosinusitis (CRS) is inflammation or infection of the sinuses that lasts at least 3 months.7 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type of CRS that affects about one-third of CRS patients4. People with CRSwNP have CRS and nasal polyps.7
Commonly used treatments for CRSwNP include:
Biologic therapies are a class of treatments produced from a living source such as cell or microorganism 10,11. They are usually administered via injection or infusion.12 The biologic treatments used for CRSwNP contain monoclonal antibodies. Monoclonal antibodies are proteins with a specific target, such as molecules involved in the inflammatory processes of CRSwNP.2,10 have been FDA-approved for CRSwNP include dupilumab, omalizumab, and mepolizumab7,11. Additional biologics currently under investigation as potential treatment for CRSwNP include benralizumab, reslizumab, and Tezepelumab.8,15,16
CRSwNP can occur together with other conditions, such as asthma, allergic rhinitis, aspirin-exacerbated respiratory disease, and sinus infections.2,8 In these cases, treatment can be managed to most effectively control multiple conditions.2,8
Patients with CRSwNP typically require long-term treatment to keep symptoms under control and and improve quality of life.8
All URLs accessed on 8/26/24.
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.